ArticleClinical rheumatology2020
Mortality of Chinese patients with polymyositis and dermatomyositis.
Article in Clinical rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- A meta-analysis of melanoma risk in idiopathic inflammatory myopathy patients.Zeitschrift fur Rheumatologie · 2024Pooled it
- Mortality in Inflammatory Rheumatic Diseases: Lithuanian National Registry Data and Systematic Review.International journal of environmental research and public health · 2021Pooled it
- Epidemiology and mortality of dermatomyositis and polymyositis in Oklahoma 2010-2023.EULAR rheumatology open · 2026Article
- Integrated proteomic and transcriptomic profiles reveals the role of OAS3 in dermatomyositis pathogenesis.Frontiers in immunology · 2026Article
- Malignant erythema as a high-specificity cutaneous indicator of malignancy in adult dermatomyositis: a retrospective cohort study.Frontiers in immunology · 2026Article
- A retrospective natural history study in adult and juvenile patients with incident dermatomyositis and polymyositis using real world data.Clinical rheumatology · 2025Observational
- Design of a randomised controlled hybrid trial of nintedanib in patients with progressive myositis-associated interstitial lung disease.BMC pulmonary medicine · 2024Article
- An Observational Study on the Clinical Characteristics and Prognosis of Patients With Interstitial Lung Disease Secondary to Dermatomyositis and Antisynthetase Syndrome.International journal of rheumatology · 2024Article
- Elevated platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio in patients with polymyositis/dermatomyositis: a retrospective study.Clinical rheumatology · 2023Article
- Article
- Long-term secular trends in dermatomyositis and polymyositis mortality in the USA from 1981 to 2020 according to underlying and multiple cause of death mortality data.Arthritis research & therapy · 2023Article
- Clinical Characteristics and Associated Factors for Infection and in-Hospital Mortality in Inpatients with Polymyositis/Dermatomyositis in China: A Retrospective Study.Infection and drug resistance · 2023Article
- Elevated spleen FDG uptake predicts unfavorable outcome in adult idiopathic-inflammatory-myopathy patients: a crisis beyond muscles.Clinical rheumatology · 2022Article
- The SNPs of mitochondrial DNA displacement loop region and mitochondrial DNA copy number associated with risk of polymyositis and dermatomyositis.Scientific reports · 2022Article
- Clinical Features of Anti-Synthetase Syndrome Associated with Prognosis in Patients with Dermatomyositis and Polymyositis.Journal of clinical medicine · 2022Article
- Ferroptosis and its role in skeletal muscle diseases.Frontiers in molecular biosciences · 2022Review
- Metagenomic next-generation sequencing shotgun for the diagnosis of infection in connective tissue diseases: A retrospective study.Frontiers in cellular and infection microbiology · 2022Article
- Analysis of risk factors of interstitial lung disease and mortality rates in Chinese patients with idiopathic inflammatory myopathy.International journal of rheumatic diseases · 2021Article
- Survival of Patients With Idiopathic Inflammatory Myopathies in Slovenia.Frontiers in medicine · 2021Article
- AST/ALT ratio as a predictor of mortality and exacerbations of PM/DM-ILD in 1 year-a retrospective cohort study with 522 cases.Arthritis research & therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the mortality and the causes of death in Chinese patients with polymyositis (PM) and dermatomyositis (DM).
methodsThe clinical data of all consecutive adult PM/DM patients in Rheumatology and clinical immunology department of Peking University First Hospital from January 2007 to Apr2016 were collected. The primary causes of death were identified, the standardized mortality ratio (SMR) and years of life lost (YLL) were calculated based on the National Bureau of Statistics of China for the general population, the survival in the first decade was performed using Kaplan-Meier analysis, and the predictors of mortality were evaluated by multivariable cox regression.
resultsA total of 85 PM and226 DM cases were included and 68 patients died. Infection (52.3%) was the leading cause of death. The overall age and sex adjusted SMR was 6.0(95%CI 3.5-8.5) for PM, and 9.0(95%CI 6.8-11.2) for DM. The YLL of women and men were 12.2 and 18.3 years respectively for PM, and 37.5 and 28.4 years respectively for DM. The 10-year survival of patients with ILD, malignancy or infection was significantly worse than those without, respectively. The independent predictors of mortality for PM/DM patients were age at disease onset, malignancy and infection.
conclusionsMortality of PM/DM patients in China is substantial, especially in females, and those with ILD, malignancy or infection. Infection was the leading cause of death. Patients with older age at onset, infection, ILD, and malignancy need to be paid more attention. Key Points • This is the first comprehensive report about the mortality situation with a large population in PM/DM patients in China including SMR, YLL, and cause of death, Kaplan-Meier survival analysis and Cox regression analysis for mortality risk factors. • The specific SMRs for PM/DM patients with malignancy and interstitial lung disease were also reported in this study. To our knowledge, only two studies worldwide reported SMRs in PM/DM patients and no figure about YLL was reported so far. • Overall, the mortality figures in this study were higher than those from the western countries, and the leading cause of death was different from the western countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.